Multiple sclerosis is not a disease of the immune system

Quarterly Review of Biology

Volumn 86, Issue 4, 2011, Pages 287-321

  Corthals, Angelique P ^a  

^a JOHN JAY COLLEGE OF CRIMINAL JUSTICE   (United States)

Author keywords

Autoimmune hypothesis; Inflammation; Lipid metabolism; Multiple sclerosis; Nuclear receptors; Peroxisomes; PPARs

Indexed keywords

FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ARTICLE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INFLAMMATION; LIPID METABOLISM; METABOLISM; MULTIPLE SCLEROSIS; PEROXISOME; RISK FACTOR; SEX RATIO;

FATTY ACIDS; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LIPID METABOLISM; MULTIPLE SCLEROSIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PEROXISOMES; RISK FACTORS; SEX DISTRIBUTION;

EID: 84855174920     PISSN: 00335770     EISSN: None     Source Type: Journal    
DOI: 10.1086/662453     Document Type: Article

References (215)

1. Ahmed R. A. M., Murao K., Imachi H., Yu X., Li J., Wong N. C. W., Ishida T. 2009. Human scavenger receptor class B type 1 is regulated by activators of peroxisome proliferators-activated receptor-α in hepatocytes. Endocrine 35:233-242.
2. Airas L., Mikkola J., Vainio J. M., Elovaara I., Smith D. J. 2006. Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. Journal of Neuroimmunology 177:132-135.
3. Allen N. J., Barres B. A. 2009. Glia-more than just brain glue. Nature 457:675-677.
4. Arababadi M. K., Hassanshahi G., Azin H., Salehabad V. A., Araste M., Pourali R., Nekhei Z. 2010. No association between CCR5-α32 mutation and multiple sclerosis in patients of southeastern Iran. Laboratory Medicine 41:31-33.
5. Ascherio A., Munger K. L. 2007. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Annals of Neurology 61:504-513.
6. Ascherio A., Munger K. L., Simon K. C. 2010. Vitamin D and multiple sclerosis. The Lancet Neurology 9:599-612.
7. Assmann G., Gotto A. M. 2004. HDL cholesterol and protective factors in atherosclerosis. Circulation 109: III-8-III-14.
8. Aupperle R. L., Denney D. R., Lynch S. G., Carlson S. E., Sullivan D. K. 2008. Omega-3 fatty acids and multiple sclerosis: relationship to depression. Journal of Behavioral Medicine 31:127-135.
9. Auwerx J., Schoonjans K., Fruchart J. C., Staels B. 1996. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. Journal of Atherosclerosis and Thrombosis 3:81-89.
10. Baes M., Aubourg P. 2009. Peroxisomes, myelination, and axonal integrity in the CNS. The Neuroscientist 15:367-379.
11. Baker P. W., Rye K.-A., Gamble J. R., Vadas M. A., Barter P. J. 2000. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. Journal of Lipid Research 41:1261-1267.
12. Barbier O. 2002. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 22:717-726.
13. Barish G. D., Atkins A. R., Downes M., Olson P., Chong L.-W., Nelson M., Zou Y., Hwang H., Kang H., Curtiss L., Evans R. M., Lee C.-H. 2008. PPAR-α regulates multiple proinflammatory pathways to suppress atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 105:4271-4276.
14. Barth H., Schnober E. K., Neumann-Haefelin C., Thumann C., Zeisel M. B., Diepolder H. M., Hu Z., Liang T. J., Blum H. E., Thimme R., Lambotin M., Baumert T. F. 2008. Scavenger receptor class B is required for Hepatitis C virus uptake and crosspresentation by human dendritic cells. Journal of Virology 82:3466-3479.
15. Baumberger C., Ulevitch R. J., Dayer J.-M. 1991. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology 59:378-383.
16. Benoist C., Mathis D. 2001. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nature Immunology 2:797-801.
17. Beretich B. D., Beretich T. M. 2010. Authors' reply to "Latitude and multiple sclerosis prevalence: vitamin D reduces risk of Epstein-Barr virus infection. " Multiple Sclerosis 16:374-375.
18. Besler H. T., Comoǧlu S. 2003. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutritional Neuroscience 6:189-196.
19. Besler H. T., Comoǧlu S., Okçu Z. 2002. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutritional Neuroscience 5:215-220.
20. Bighetti E. J. B., Patrício P. R., Casquero A. C., Berti J. A., Oliveira H. C. F. 2009. Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver. Lipids in Health and Disease 8:50.
21. Bishop-Bailey D., Bystrom J. 2009. Emerging roles of peroxisome proliferator-activated receptor-α/β in inflammation. Pharmacology and Therapeutics 124: 141-150.
22. Blecharz K. G., Haghikia A., Stasiolek M., Kruse N., Drenckhahn D., Gold R., Roewer N., Chan A., Förster C. Y. 2010. Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Multiple Sclerosis 16:293-302.
23. Blewett M. M. 2010. Lipid autoreactivity in multiple sclerosis. Medical Hypotheses 74:433-442.
24. Bocher V., Pineda-Torra I., Fruchart J.-C., Staels B. 2002. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Annals of the New York Academy of Sciences 967:7-18.
25. Bostom A. G., Silbershatz H., Rosenberg I. H., Selhub J., D'Agostino R. B., Wolf P. A., Jacques P. F., Wilson P. W. F. 1999. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Archives of Internal Medicine 159:1077-1080.
26. Boullier A., Bird D. A., Chang M.-K., Dennis E. A., Friedman P., Gillotte-Taylor K., Hörkkö S., Palinski W., Quehenberger O., Shaw P., Steinberg D., Terpstra V., Witztum J. L. 2001. Scavenger receptors, oxidized LDL, and atherosclerosis. Annals of the New York Academy of Sciences 947:214-223.
27. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 137:354-366.
28. Broadley S. A. 2007. Could vitamin D be the answer to multiple sclerosis? Multiple Sclerosis 13:825-826.
29. Brodeur M. R., Brissette L., Falstrault L., Moreau R. 2008. HDL3 reduces the association and modulates the metabolism of oxidized LDL by osteoblastic cells: a protection against cell death. Journal of Cellular Biochemistry 105:1374-1385.
30. Brown J. D., Plutzky J. 2007. Peroxisome proliferatoractivated receptors as transcriptional nodal points and therapeutic targets. Circulation 115:518-533.
31. Burger D., Dayer J.-M. 2002. High-density lipoproteinassociated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmunity Reviews 1:111-117.
32. Calabresi P. A., Austin H., Racke M. K., Goodman A., Choyke P., Maloni H., McFarland H. F. 2002. Impaired renal function in progressive multiple sclerosis. Neurology 59:1799-1801.
33. Calder P. C. 1999. Dietary fatty acids and the immune system. Lipids 34:S137-S140.
34. Calkin A. C., Giunti S., Jandeleit-Dahm K. A., Allen T. J., Cooper M. E., Thomas M. C. 2006. PPAR-α and-γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrology Dialysis Transplantation 21:2399-2405.
35. Cantorna M. T. 2008. Vitamin D and multiple sclerosis: an update. Nutrition Reviews 66:S135-S138.
36. Carson M. J., Thrash J. C., Lo D. 2004. Analysis of microglial gene expression: identifying targets for CNS neurodegenerative and autoimmune disease. American Journal of PharmacoGenomics 4:321-330.
37. Catanese M. T., Ansuini H., Graziani R., Huby T., Moreau M., Ball J. K., Paonessa G., Rice C. M., Cortese R., Vitelli A., Nicosia A. 2010. Role of scavenger receptor class B type I in Hepatitis C virus entry: kinetics and molecular determinants. Journal of Virology 84:34-43.
38. Challoner P. B., Smith K. T., Parker J. D., MacLeod D. L., Coulter S. N., Rose T. M., Schultz E. R., Bennett J. L., Garber R. L., Chang M. 1995. Plaqueassociated expression of human herpesvirus 6 in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 92:7440-7444.
39. Chen S.-K., Tvrdik P., Peden E., Cho S., Wu S., Spangrude G., Capecchi M. R. 2010. Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. Cell 141:775-785.
40. Cheng C.-F., Chen H.-H., Lin H. 2010. Role of PPAR-α and its agonist in renal diseases. PPAR Research 2010: 345098.
41. Cho S., Park E.-M., Febbraio M., Anrather J., Park L., Racchumi G., Silverstein R. L., Iadecola C. 2005. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. Journal of Neuroscience 25:2504-2512.
42. Cho M.-C., Lee K., Paik S.-G., Yoon D.-Y. 2008. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Research 2008: 679137.
43. Chrast R., Saher G., Nave K.-A., Verheijen M. H. G. 2011. Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models. Journal of Lipid Research 52:419-434.
44. Ciana P., Biserni A., Tatangelo L., Tiveron C., Sciarroni A. F., Ottobrini L., Maggi A. 2007. A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver. Molecular Endocrinology 21: 388-400.
45. Coker G. T., Vinnedge L., O'Malley K. L. 1988. Characterization of rat and human tyrosine hydroxylase genes: functional expression of both promoters in neuronal and non-neuronal cell types. Biochemical and Biophysical Research Communications 157:1341-1347.
46. Collino M., Aragno M., Mastrocola R., Benetti E., Gallicchio M., Dianzani C., Danni O., Thiemermann C., Fantozzi R. 2006. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-α agonist WY14643. Free Radical Biology and Medicine 41:579-589.
47. Coltel N., Combes V., Wassmer S. C., Chimini G., Grau G. E. 2006. Cell vesiculation and immunopathology: implications in cerebral malaria. Microbes and Infection 8:2305-2316.
48. Comabella M., Montalban X., Horga A., Messmer B., Kakalacheva K., Strowig T., Caballero E., Münz C., Lünemann J. D. 2010. Antiviral immune response in patients with multiple sclerosis and healthy siblings. Multiple Sclerosis 16:355-358.
49. Combes V., Coltel N., Faille D., Wassmer S. C., Grau G. E. 2006. Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. International Journal for Parasitology 36:541-546.
50. Cosulich S., James N., Roberts R. 2000. Role of MAP kinase signalling pathways in the mode of action of peroxisome proliferators. Carcinogenesis 21:579-584.
51. Cunha-Rodrigues M., Portugal S., Febbraio M., Mota M. M. 2007. Bone marrow chimeric mice reveal a dual role for CD36 in Plasmodium berghei ANKA infection. Malaria Journal 6:32.
52. Cunnane S. C., Ho S.-Y., Dore-Duffy P., Ells K. R., Horrobin D. F. 1989. Essential fatty acid and lipid profiles in plasma and erythrocytes in patients with multiple sclerosis. American Journal of Clinical Nutrition 50:801-806.
53. D'Angelo B., Benedetti E., Di Loreto S., Cristiano L., Laurenti G., Cerù M. P., Cimini A. 2011. Signal transduction pathways involved in PPAR-α/β-induced neuronal differentiation. Journal of Cellular Physiology 226:2170-2180.
54. Dalgas U., Stenager E., Jakobsen J., Petersen T., Hansen H. J., Knudsen C., Overgaard K., Ingemann-Hansen T. 2009. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 73:1478-1484.
55. Davalos D., Grutzendler J., Yang G., Kim J. V., Zuo Y., Jung S., Littman D. R., Dustin M. L., Gan W.-B. 2005. ATP mediates rapid microglial response to local brain injury in vivo. Nature Neuroscience 8:752-758.
56. Davidson M. H. 2006. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. American Journal of Cardiology 98(Supplement 1):27-33.
57. De Souza-Teixeira F., Costilla S., Ayán C., García-López D., González-Gallego J., de Paz J. A. 2009. Effects of resistance training in multiple sclerosis. International Journal of Sports Medicine 30:245-250.
58. DeAngelis T., Lublin, F. 2008. Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. Mount Sinai Journal of Medicine 75: 157-167.
59. Devlin A. M., Lentz S. R. 2006. ApoA-I: a missing link between homocysteine and lipid metabolism? Circulation Research 98:431-433.
60. Dressel U., Allen T. L., Pippal J. B., Rohde P. R., Lau P., Muscat G. E. O. 2003. The peroxisome proliferatoractivated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Molecular Endocrinology 17:2477-2493.
61. Drew P. D., Xu J., Racke M. K. 2008. PPAR-α: therapeutic potential for multiple sclerosis. PPAR Research 2008:627463.
62. Duan S. Z., Usher M. G., Mortensen R. M. 2008. Peroxisome proliferator-activated receptor-α-mediated effects in the vasculature. Circulation Research 102:283-294.
63. Dujmovic I., Pekmezovic T., Obrenovic R., Nikolić A., Spasic M., Mostarica Stojkovic M., Drulovic J. 2009. Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis. Clinical Chemistry and Laboratory Medicine 47:848-853.
64. Dunn S. E., Ousman S. S., Sobel R. A., Zuniga L., Baranzini S. E., Youssef S., Crowell A., Loh J., Oksenberg J., Steinman L. 2007. Peroxisome proliferator-activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cellmediated autoimmunity. Journal of Experimental Medicine 204:321-330.
65. Ehrenborg E., Krook A. 2009. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor α. Pharmacological Reviews 61:373-393.
66. Elshorbagy A. K., Nurk E., Gjesdal C. G., Tell G. S., Ueland P. M., Nygård O., Tverdal A., Vollset S. E., Refsum H. 2008. Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism? American Journal of Clinical Nutrition 88:738-746.
67. Evans R. M., Barish G. D., Wang Y.-X. 2004. PPARs and the complex journey to obesity. Nature Medicine 10: 355-361.
68. Eyles D. W., Smith S., Kinobe R., Hewison M., McGrath J. J. 2005. Distribution of the vitamin D receptor and 1β-hydroxylase in human brain. Journal of Chemical Neuroanatomy 29:21-30.
69. Febbraio M., Hajjar D. P., Silverstein R. L. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. Journal of Clinical Investigation 108:785-791.
70. Fensterl V., Sen G. C. 2009. Interferons and viral infections. BioFactors 35:14-20.
71. Ferrandi C., Richard F., Tavano P., Hauben E., Barbié V., Gotteland J.-P., Greco B., Fortunato M., Mariani M. F., Furlan R., Comi G., Martino G., Zaratin P. F. 2011. Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Multiple Sclerosis 17:43-56.
72. Ferretti G., Bacchetti T., Principi F., Di Ludovico F., Viti B., Angeleri V. A., Danni M., Provinciali L. 2005. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Multiple Sclerosis 11:677-682.
73. Fruchart J.-C. 2001. Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism. American Journal of Cardiology 88:24-29.
74. Fruchart J.-C. 2007. Novel peroxisome proliferator activated receptor-γ agonists. American Journal of Cardiology 100:S41-S46.
75. Fukagawa N. K., Martin J. M., Wurthmann A., Prue A. H., Ebenstein D., O'Rourke B. 2000. Sex-related differences in methionine metabolism and plasma homocysteine concentrations. American Journal of Clinical Nutrition 72:22-29.
76. Glazer R. I., Yuan H., Xie Z., Yin Y. 2008. PPAR-α and PPAR-α as modulators of neoplasia and cell fate. PPAR Research 2008:247379.
77. Goldman M. D., Cohen J. A. 2008. Statins to treat multiple sclerosis: friend or foe? Neurology 71:1386-1387.
78. Grant W. B. 2010. Latitude and multiple sclerosis prev-alence: vitamin D reduces risk of Epstein-Barr virus infection. Multiple Sclerosis 16:373.
79. Greer J. M., McCombe P. A. 2011. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. Journal of Neuroimmunology 234: 7-18.
80. Habek M., Hojsak I., Brinar V. V. 2010. Nutrition in multiple sclerosis. Clinical Neurology and Neurosurgery 112:616-620.
81. Haider L., Fischer M. T., Frischer J. M., Bauer J., Höftberger R., Botond G., Esterbauer H., Binder C. J., Witztum J. L., Lassmann H. 2011. Oxidative damage in multiple sclerosis lesions. Brain 134:1914-1924.
82. Hall M. G., Quignodon L., Desvergne B. 2008. Peroxisome proliferator-activated receptor β/δ in the brain: facts and hypothesis. PPAR Research 2008: 780452.
83. Hammarstedt A., Andersson C. X., Rotter Sopasakis V., Smith U. 2005. The effect of PPAR-α ligands on the adipose tissue in insulin resistance. Prostaglandins, Leukotrienes and Essential Fatty Acids 73:65-75.
84. Hanafy K. A., Sloan J. A. 2011. Regulation of remyelination in multiple sclerosis. FEBS Letters doi:10.1016/j.febslet.2011.03.048.
85. Handschin C. 2010. Regulation of skeletal muscle cell plasticity by the peroxisome proliferator-activated receptor α coactivator 1α. Journal of Receptor and Signal Transduction Research 30:376-384.
86. Handschin C., Rhee J., Lin J., Tarr P. T., Spiegelman B. M. 2003. An autoregulatory loop controls peroxisome proliferator-activated receptor γ coactivator 1α expression in muscle. Proceedings of the National Academy of Sciences of the United States of America 100: 7111-7116.
87. Harris S. G., Phipps R. P. 2001. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. European Journal of Immunology 31:1098-1105.
88. Haselkorn J. K., Loomis S. 2005. Multiple sclerosis and spasticity. Physical Medicine and Rehabilitation Clinics of North America 16:467-481.
89. Hawkes M., Li X., Crockett M., Diassiti A., Finney C., Min-Oo G., Liles W. C., Liu J., Kain K. C. 2010. CD36 deficiency attenuates experimental mycobacterial infection. BMC Infectious Diseases 10:299.
90. Hayden M. R. 2008. Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors. Journal of the CardioMetabolic Syndrome 3:70-71.
91. Hayden M. R., Tyagi S. C. 2004. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutrition Journal 3:4.
92. Heinecke J. W. 2009. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. Journal of Lipid Research 50:S167-S171.
93. Herzig S., Hedrick S., Morantte I., Koo S.-H., Galimi F., Montminy M. 2003. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-α. Nature 426:190-193.
94. Holman R. T., Johnson S. B., Kokmen E. 1989. Deficiencies of polyunsaturated fatty acids and replacement by nonessential fatty acids in plasma lipids in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 86:4720-4724.
95. Hoon Lee J., Joe E.-H., Jou I. 2005. PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. NeuroReport 16: 829-833.
96. Hou R. C.-W., Wu C.-C., Huang J.-R., Chen Y.-S., Jeng K.-C. G. 2005. Oxidative toxicity in BV-2 microglia cells: sesamolin neuroprotection of H2O2 injury involving activation of p38 mitogen-activated protein kinase. Annals of the New York Academy of Sciences 1042: 279-285.
97. Huang S.-H., Jong A. Y. 2001. Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier. Cellular Microbiology 3:277-287.
98. Hulshagen L., Krysko O., Bottelbergs A., Huyghe S., Klein R., Van Veldhoven P. P., De Deyn P. P., D'Hooge R., Hartmann D., Baes M. 2008. Absence of functional peroxisomes from mouse CNS causes dysmyelination and axon degeneration. Journal of Neuroscience 28:4015-4027.
99. Hunt M. J., Tyagi S. C. 2002. Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. American Journal of Physiology-Cell Physiology 283:C1073-C1079.
100. Inuzuka M., Hayakawa M., Ingi T. 2005. Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis. Journal of Biological Chemistry 280:35776-35783.
101. Isobe N., Matsushita T., Yamasaki R., Ramagopalan S. V., Kawano Y., Nishimura Y., Ebers G. C., Kira J. 2010. Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Multiple Sclerosis 16:147-155.
102. Jalouli M., Carlsson L., Améen C., Lindén D., Ljungberg A., Michalik L., Edén S., Wahli W., Oscarsson J. 2003. Sex difference in hepatic peroxisome proliferatoractivated receptor α expression: influence of pituitary and gonadal hormones. Endocrinology 144:101-109.
103. Jamroz-Wisniewska A., Beltowski J., Stelmasiak Z., Bartosik-Psujek H. 2009. Paraoxonase 1 activity in different types of multiple sclerosis. Multiple Sclerosis 15:399-402.
104. Janabi M., Yamashita S., Hirano K., Sakai N., Hiraoka H., Matsumoto K., Zhang Z., Nozaki S., Matsuzawa Y. 2000. Oxidized LDL-induced NF-αB activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arteriosclerosis, Thrombosis, and Vascular Biology 20:1953-1960.
105. Jiang Y., Zhang J., Xiong J., Cao J., Li G., Wang S. 2007. Ligands of peroxisome proliferator-activated receptor inhibit homocysteine-induced DNA methylation of inducible nitric oxide synthase gene. Acta Biochimica et Biophysica Sinica 39:366-376.
106. Khovidhunkit W., Kim M.-S., Memon R. A., Shigenaga J. K., Moser A. H., Feingold K. R., Grunfeld C. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. Journal of Lipid Research 45: 1169-1196.
107. Kim H.-S., Hong S. J., LeDoux M. S., Kim K.-S. 2001. Regulation of the tyrosine hydroxylase and dopamine β-hydroxylase genes by the transcription factor AP-2. Journal of Neurochemistry 76:280-294.
108. Kim B., Kaistha S. D., Rouse B. T. 2006. Viruses and autoimmunity. Autoimmunity 39:71-77.
109. Kofler J., Wiley C. A. 2011. Microglia: key innate immune cells of the brain. Toxicologic Pathology 39:103-114.
110. Kota B. P., Huang T. H.-W., Roufogalis B. D. 2005. An overview on biological mechanisms of PPARs. Pharmacological Research 51:85-94.
111. Ladeby R., Wirenfeldt M., García-Ovejero D., Fenger C., Dissing-Olesen L., Dalmau I., Finsen B. 2005. Microglial cell population dynamics in the injured adult central nervous system. Brain Research Reviews 48: 196-206.
112. Lee H., Cha S., Lee M.-S., Cho G. J., Choi W. S., Suk K. 2003. Role of antiproliferative B cell translocation gene-1 as an apoptotic sensitizer in activationinduced cell death of brain microglia. Journal of Immunology 171:5802-5811.
113. Li L., Pan R., Li R., Niemann B., Aurich A.-C., Chen Y., Rohrbach S. 2011. Mitochondrial biogenesis and peroxisome proliferator-activated receptor-α coactivator-1α (PGC-1α) deacetylation by physical activity: intact adipocytokine signaling is required. Diabetes 60:157-167.
114. Lim J. S., Mietus-Snyder M., Valente A., Schwarz J.-M., Lustig R. H. 2010. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nature Reviews Gastroenterology and Hepatology 7:251-264.
115. Love W. C., Cashell A., Reynolds M., Callaghan N. 1974. Linoleate and fatty-acid patterns of serum lipids in multiple sclerosis and other diseases. British Medical Journal 3:18-21.
116. Luc G., Jacob N., Bouly M., Fruchart J.-C., Staels B., Giral P. 2004. Fenofibrate increases homocystinemia through a PPAR-α-mediated mechanism. Journal of Cardiovascular Pharmacology 43:452-453.
117. Lunde I. G., Ekmark M., Rana Z. A., Buonanno A., Gundersen K. 2007. PPAR-α expression is influenced by muscle activity and induces slow muscle properties in adult rat muscles after somatic gene transfer. Journal of Physiology 582:1277-1287.
118. Lünemann J. D., Tintoré M., Messmer B., Strowig T., Rovira Á., Perkal H., Caballero E., Münz C., Montalban X., Comabella M. 2010. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Annals of Neurology 67:159-169.
119. Maghzi A. H., Ghazavi H., Ahsan M., Etemadifar M., Mousavi S. A., Khorvash F., Minagar A. 2010. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. Multiple Sclerosis 16:359-361.
120. Magkos F., Mittendorfer B. 2009. Gender differences in lipid metabolism and the effect of obesity. Obstetrics and Gynecology Clinics of North America 36:245-265, vii.
121. Malchiodi-Albedi F., Matteucci A., Bernardo A., Minghetti L. 2008. PPAR-α, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches. PPAR Research 2008:295784.
122. Mandosi E., Fallarino M., Gatti A., Carnovale A., Rossetti M., Lococo E., Buchetti B., Filetti S., Lenti L., Morano S. 2010. Atorvastatin downregulates monocyte CD36 expression, nuclear NFκB and TNFα levels in type 2 diabetes. Journal of Atherosclerosis and Thrombosis 17:539-545.
123. Marinou K., Adiels M., Hodson L., Frayn K. N., Karpe F., Fielding B. A. 2011. Young women partition fatty acids towards ketone body production rather than VLDL-TAG synthesis, compared with young men. British Journal of Nutrition 105:857-865.
124. Marshall B. H. 1991. Lipids and neurological diseases. Medical Hypotheses 34:272-274.
125. Marsillach J., Camps J., Ferré N., Beltran R., Rull A., Mackness B., Mackness M., Joven J. 2009. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterology 9:3.
126. Massa J., O'Reilly E., Munger K. L., DeLorenze G. N., Ascherio A. 2009. Serum uric acid and risk of multiple sclerosis. Journal of Neurology 256:1643-1648.
127. McCoy L., Tsunoda I., Fujinami R. S. 2006. Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 39:9-19.
128. McCully K. S., Olszewski A. J., Vezeridis M. P. 1990. Homocysteine and lipid metabolism in atherogenesis: effect of the homocysteine thiolactonyl derivatives, thioretinaco and thioretinamide. Atherosclerosis 83:197-206.
129. McKenna N. J., Cooney A. J., DeMayo F. J., Downes M., Glass C. K., Lanz R. B., Lazar M. A., Mangelsdorf D. J., Moore D. D., Qin J., Steffen D. L., Tsai M.-J., Tsai S. Y., Yu R., Margolis R. N., Evans R. M., O'Malley B. W. 2009. Minireview: evolution of NURSA, the nuclear receptor signaling atlas. Molecular Endocrinology 23:740-746.
130. Mehta L. R., Dworkin R. H., Schwid S. R. 2009. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nature Clinical Practice Neurology 5:82-92.
131. Midgard R., Riise T., Nyland H. 1991. Epidemiologic trends in multiple sclerosis in Møre and Romsdal, Norway: a prevalence/incidence study in a stable population. Neurology 41:887-892.
132. Mikael L. G., Genest J., Rozen R. 2006. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circulation Research 98:564-571.
133. Mirabelli-Badenier M., Braunersreuther V., Viviani G. L., Dallegri F., Quercioli A., Veneselli E., Mach F., Montecucco F. 2011. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thrombosis and Haemostasis 105:409-420.
134. Moller D. E., Berger J. P. 2003. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. International Journal of Obesity 27(Supplement 3):S17-S21.
135. Monk P. N., Shaw P. J. 2006. ALS: life and death in a bad neighborhood. Nature Medicine 12:885-887.
136. Mudd S. H., Poole J. R. 1975. Labile methyl balances for normal humans on various dietary regimens. Metabolism Clinical and Experimental 24:721-735.
137. Niino M., Kikuchi S., Fukazawa T., Yabe I., Tashiro K. 2002. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. Journal of Neuroimmunology 127:177-179.
138. Nimmerjahn A., Kirchhoff F., Helmchen F. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-1318.
139. Nygård O., Nordrehaug J. E., Refsum H., Ueland P. M., Farstad M., Vollset S. E. 1997. Plasma homocysteine levels and mortality in patients with coronary artery disease. New England Journal of Medicine 337:230-237.
140. Oksenberg J. R., Baranzini S. E., Sawcer S., Hauser S. L. 2008. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nature Reviews Genetics 9:516-526.
141. Paintlia A. S., Paintlia M. K., Singh I., Singh A. K. 2006. IL-4-induced peroxisome proliferator-activated receptor α activation inhibits NF-κB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: implication for CNSdemyelinating diseases. Journal of Immunology 176: 4385-4398.
142. Paumen M. B., Ishida Y., Muramatsu M., Yamamoto M., Honjo T. 1997. Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. Journal of Biological Chemistry 272:3324-3329.
143. Pérez-Martínez P., Pérez-Jiménez F., Bellido C., Ordovás J. M., Moreno J. A., Marín C., Gómez P., Delgado-Lista J., Fuentes F., López-Miranda J. 2005. A polymorphism exon 1 variant at the locus of the scavenger receptor class B type I (SCARB1) gene is associated with differences in insulin sensitivity in healthy people during the consumption of an olive oil-rich diet. Journal of Clinical Endocrinology and Metabolism 90:2297-2300.
144. Peters J. M., Lee S. S. T., Li W., Ward J. M., Gavrilova O., Everett C., Reitman M. L., Hudson L. D., Gonzalez F. J. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Molecular and Cellular Biology 20:5119-5128.
145. Peters J. M., Aoyama T., Burns A. M., Gonzalez F. J. 2003. Bezafibrate is a dual ligand for PPAR-α and PPAR-α: studies using null mice. Biochimica et Biophysica Acta 1632:80-89.
146. Philips J. A., Rubin E. J., Perrimon N. 2005. Drosophila RNAi screen reveals CD36 family member required for mycobacterial infection. Science 309:1251-1253.
147. Podrez E. A., Febbraio M., Sheibani N., Schmitt D., Silverstein R. L., Hajjar D. P., Cohen P. A., Frazier W. A., Hoff H. F., Hazen S. L. 2000. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. Journal of Clinical Investigation 105: 1095-1108.
148. Poser C. M. 1994. The epidemiology of multiple sclerosis: a general overview. Annals of Neurology 36:S180-S193.
149. Qin H., Roberts K. L., Niyongere S. A., Cong Y., Elson C. O., Benveniste E. N. 2007. Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia. Journal of Immunology 179:5966-5976.
150. Rai T. S., Khullar M., Sehrawat B. S., Ahuja M., Sharma P. K., Vijayvergiya R., Grover A. 2008. Synergistic effect between apolipoprotein E and apolipoprotein A1 gene polymorphisms in the risk for coronary artery disease. Molecular and Cellular Biochemistry 313: 139-146.
151. Ramagopalan S. V., Maugeri N. J., Handunnetthi L., Lincoln M. R., Orton S.-M., Dyment D. A, DeLuca G. C., Herrera B. M., Chao M. J., Sadovnick A. D., Ebers G. C., Knight J. C. 2009. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genetics 5:e1000369.
152. Raman D., Sobolik-Delmaire T., Richmond A. 2011. Chemokines in health and disease. Experimental Cell Research 317:575-589.
153. Ramsaransing G. S. M., Fokkema M. R., Teelken A., Arutjunyan A. V., Koch M., De Keyser J. 2006. Plasma homocysteine levels in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 77: 189-192.
154. Rinaldi B., Donniacuo M., Esposito E., Capuano A., Sodano L., Mazzon E., Di Palma D., Paterniti I., Cuzzocrea S., Rossi F. 2011. PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. British Journal of Pharmacology 163:609-623.
155. Ritter M. R., Banin E., Moreno S. K., Aguilar E., Dorrell M. I., Friedlander M. 2006. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. Journal of Clinical Investigation 116:3266-3276.
156. Roberts C. K., Liang K., Barnard R. J., Kim C. H., Vaziri N. D. 2004. HMG-CoA reductase, cholesterol 7β-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X. Kidney International 66: 1503-1511.
157. Rock R. B., Gekker G., Hu S., Sheng W. S., Cheeran M., Lokensgard J. R., Peterson P. K. 2004. Role of microglia in central nervous system infections. Clinical Microbiology Reviews 17:942-964.
158. Rook G. A. W. 2009. Review series on helminths, immune modulation and the hygiene hypothesis: the broader implications of the hygiene hypothesis. Immunology 126:3-11.
159. Rosati G. 2001. The prevalence of multiple sclerosis in the world: an update. Neurological Sciences 22:117-139.
160. Rubic T., Trottmann M., Lorenz R. L. 2004. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochemical Pharmacology 67:411-419.
161. Ruby M. A., Goldenson B., Orasanu G., Johnston T. P., Plutzky J., Krauss R. M. 2010. VLDL hydrolysis by LPL activates PPAR-α through generation of unbound fatty acids. Journal of Lipid Research 51:2275-2281.
162. Rusyn I., Rose M. L., Bojes H. K., Thurman R. G. 2000. Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators. Antioxidants and Redox Signaling 2:607-621.
163. Sahni S. K. 2007. Endothelial cell infection and hemostasis. Thrombosis Research 119:531-549.
164. Sassi S., Cosmi B., Palareti G., Legnani C., Grossi G., Musolesi S., Coccheri S. 2002. Influence of age, sex and vitamin status on fasting and post-methionine load plasma homocysteine levels. Haematologica 87: 957-964.
165. Savkur R. S., Bramlett K. S., Stayrook K. R., Nagpal S., Burris T. P. 2005. Coactivation of the human vitamin D receptor by the peroxisome proliferator-activated receptor α coactivator-1α. Molecular Pharmacology 68: 511-517.
166. Schoonjans K., Staels B., Auwerx J. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Journal of Lipid Research 37:907-925.
167. Schrader M., Fahimi H. D. 2008. The peroxisome: still a mysterious organelle. Histochemistry and Cell Biology 129:421-440.
168. Schreiber K., Oturai A. B., Ryder L. P., Madsen H. O., Jørgensen O. S., Svejgaard A., Sorensen P. S. 2002. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLADRB1* 1501, CCR5 deletion mutation, apolipoprotein E). Multiple Sclerosis 8:295-298.
169. Schwarz S., Leweling H. 2005. Multiple sclerosis and nutrition. Multiple Sclerosis 11:24-32.
170. Sena A., Pedrosa R., Morais M. G. 2007. Beneficial effect of statins in multiple sclerosis: is it dose-dependent? Atherosclerosis 191:462.
171. Sertznig P., Dunlop T., Seifert M., Tilgen W., Reichrath J. 2009. Cross-talk between vitamin D receptor (VDR)-and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Anticancer Research 29:3647-3658.
172. Sharma A. M., Staels B. 2007. Peroxisome proliferatoractivated receptor α and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. Journal of Clinical Endocrinology and Metabolism 92:386-395.
173. Sheremata W. A., Jy W., Horstman L. L., Ahn Y. S., Alexander J. S., Minagar A. 2008. Evidence of platelet activation in multiple sclerosis. Journal of Neuroinflammation 5:27.
174. Shi Y., Burn P. 2004. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nature Reviews Drug Discovery 3:695-710.
175. Simon K. C., Munger K. L., Yang X., Ascherio A. 2010. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Multiple Sclerosis 16:133-138.
176. Singh J., Verma N. K., Kansagra S. M., Kate B. N., Dey C. S. 2007. Altered PPAR-α expression inhibits myogenic differentiation in C2C12 skeletal muscle cells. Molecular and Cellular Biochemistry 294:163-171.
177. Sladkova V., Mareš J., Lubenova B., Zapletalova J., Stejskal D., Hlustik P., Kanovsky P. 2011. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsingremitting course of disease and after clinical isolated syndrome. Neurological Research 33:415-420.
178. Small D. H., Carnegie P. R., Anderson R. McD. 1981. Cycloleucine-induced vacuolation of myelin is associated with inhibition of protein methylation. Neuroscience Letters 21:287-292.
179. Sombekke M. H., Arteta D., van de Wiel M. A., Crusius J. B. A., Tejedor D., Killestein J., Martínez A., Peña A. S., Polman C. H., Uitdehaag B. M. J. 2010. Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis. Multiple Sclerosis 16: 652-659.
180. Sprecher D. L., Massien C., Pearce G., Billin A. N., Perlstein I., Willson T. M., Hassall D. G., Ancellin N., Patterson S. D., Lobe D. C., Johnson T. G. 2007. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor α agonist. Arteriosclerosis, Thrombosis, and Vascular Biology 27:359-365.
181. Stefano J. T., de Oliveira C. P. M. S., Corrêa-Giannella M. L., de Lima V. M. R., de Sá S. V., de Oliveira E. P., de Mello E. S., Giannella-Neto D., Alves V. A. F., Carrilho F. J. 2007. Nonalcoholic steatohepatitis (NASH) in OB/OB mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferatoractivated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Digestive Diseases and Sciences 52:3448-3454.
182. Stüve O., Prod'homme T., Slavin A., Youssef S., Dunn S., Steinman L., Zamvil S. S. 2003. Statins and their potential targets in multiple sclerosis therapy. Expert Opinion on Therapeutic Targets 7:613-622.
183. Sue Y.-M., Chung C.-P., Lin H., Chou Y., Jen C.-Y., Li H.-F., Chang C.-C., Juan S.-H. 2009. PPAR-α-mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells. American Journal of Physiology-Cell Physiology 297:C321-C329.
184. Sundaram M., Yao Z. 2010. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutrition and Metabolism 7:35.
185. Svejgaard A. 2008. The immunogenetics of multiple sclerosis. Immunogenetics 60:275-286.
186. Svensson P.-A., Englund M. C. O., Snäckestrand M. S. C., Hägg D. A., Ohlsson B. G., Stemme V., Mattsson-Hulten L., Thelle D. S., Fagerberg B., Wiklund O., Carlsson L. M. S., Carlsson B. 2005. Regulation and splicing of scavenger receptor class B type I in human macrophages and atherosclerotic plaques. BMC Cardiovascular Disorders 5:25.
187. Takata Y., Kitami Y., Yang Z.-H., Nakamura M., Okura T., Hiwada K. 2002. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-α and peroxisome proliferator-activated receptor-α. Circulation Research 91:427-433.
188. Thomas D. M., Francescutti-Verbeem D. M., Kuhn D. M. 2006. Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage. FASEB Journal 20:515-517.
189. Tienari P., Bonetti A., Pihlaja H., Saastamoinen K.-P., Rantamäki T. 2006. Multiple sclerosis in G: genes and geography. Clinical Neurology and Neurosurgery 108:223-226.
190. Tilbery C. P., Atra M., Oliveira A. S. B., Calia L. A., Schmidt B. 1989. Histochemical study of the skeletal muscle in multiple sclerosis. Arquivos de Neuro-Psiquiatria 47:337-345.
191. Trigatti B. L., Krieger M., Rigotti A. 2003. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 23:1732-1738.
192. Tufekci K. U., Oner M. G., Genc S., Genc K. 2011. MicroRNAs and multiple sclerosis. Autoimmune Diseases 2011:807426.
193. Van der Mei I. A. F., Simpson S., Stankovich J., Taylor B. V. 2011. Individual and joint action of environmental factors and risk of MS. Neurologic Clinics 29: 233-255.
194. Van Eck M., Bos I. S. T., Hildebrand R. B., Van Rij B. T., Van Berkel T. J. C. 2004. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. American Journal of Pathology 165:785-794.
195. VanAmerongen B. M., Dijkstra C. D., Lips P., Polman C. H. 2004. Multiple sclerosis and vitamin D: an update. European Journal of Clinical Nutrition 58:1095-1109.
196. Varga T., Czimmerer Z., Nagy L. 2011. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochimica et Biophysica Acta 1812:1007-1022.
197. Vergeer M., Korporaal S. J. A., Franssen R., Meurs I., Out R., Hovingh G. K., Hoekstra M., Sierts J. A., Dallinga-Thie G. M., Motazacker M. M., Holleboom A. G., Van Berkel T. J. C., Kastelein J. J. P, Van Eck M., Kuivenhoven J. A. 2011. Genetic variant of the scavenger receptor BI in humans. New England Journal of Medicine 364:136-145.
198. Voskuhl R. R. 2011. Sex differences in autoimmune diseases. Biology of Sex Differences 2:1.
199. Wagner K.-D., Wagner N. 2010. Peroxisome proliferatoractivated receptor beta/delta (PPAR-α/β) acts as regulator of metabolism linked to multiple cellular functions. Pharmacology and Therapeutics 125:423-435.
200. Wake H., Moorhouse A. J., Jinno S., Kohsaka S., Nabekura J. 2009. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. Journal of Neuroscience 29:3974-3980.
201. Wang T. J., Zhang F., Richards J. B., et al. 2010. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet 376: 180-188.
202. Wang X. X., Jiang T., Shen Y., Santamaria H., Solis N., Arbeeny C., Levi M. 2011. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. American Journal of Physiology-Renal Physiology 300:F801-F810.
203. Weiner H. L. 2009. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Annals of Neurology 65:239-248.
204. White L. J., McCoy S. C., Castellano V., Gutierrez G., Stevens J. E., Walter G. A., Vandenborne K. 2004. Resistance training improves strength and functional capacity in persons with multiple sclerosis. Multiple Sclerosis 10:668-674.
205. Williams C. M. 2004. Lipid metabolism in women. Proceedings of the Nutrition Society 63:153-160.
206. Witherick J., Wilkins A., Scolding N., Kemp K. 2010. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Diseases 2011:164608.
207. Xu J., Racke M. K., Drew P. D. 2007. Peroxisome proliferator-activated receptor-α agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. Journal of Neurochemistry 103:1801-1810.
208. Yamasaki K., Kira J.-I., Kawano Y., Kobayashi T., Kanai T., Nishimura Y., Matsushita S., Hasuo K., Tobimatsu S. 1996. Western versus Asian types of multiple sclerosis immunogenetically and clinically distinct disorders. Annals of Neurology 40:569-574.
209. Yang W.-L., Frucht H. 2001. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22: 1379-1383.
210. Yilmaz M., Bukan N., Ayvaz G., Karakoç A., Törüner F., Çakir N., Arslan M. 2005. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Human Reproduction 20:3333-3340.
211. Yoshikawa T., Ide T., Shimano H., Yahagi N., Amemiya-Kudo M., Matsuzaka T., Yatoh S., Kitamine T., Okazaki H., Tamura Y., Sekiya M., Takahashi A., Hasty A. H., Sato R., Sone H., Osuga J.-I., Ishibashi S., Yamada N. 2003. Cross-talk between peroxisome proliferator-activated receptor (PPAR)α and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Molecular Endocrinology 17: 1240-1254.
212. Yousefipour Z., Oyekan A., Newaz M. 2010. Interaction of oxidative stress, nitric oxide and peroxisome proliferator activated receptor α in acute renal failure. Pharmacology and Therapeutics 125:436-445.
213. Yu K. C.-W., Cooper A. D. 2001. Postprandial lipoproteins and atherosclerosis. Frontiers in Bioscience 6:D332-D354.
214. Zhang S. M., Willett W. C., Hernán M. A., Olek M. J., Ascherio A. 2000. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. American Journal of Epidemiology 152:1056-1064.
215. Zordoky B. N. M., El-Kadi A. O. S. 2010. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacology and Therapeutics 125:446-463.